Long-term follow-up results from the phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing multiple sclerosis (RMS)

被引：0

作者：

Fox, E. ^{[1
]}

Wray, S. ^{[2
]}

Shubin, R. ^{[3
]}

Lovett-Racke, A. ^{[4
]}

Huang, D. ^{[5
]}

Bass, A. ^{[6
]}

Weiss, M. ^{[7
]}

Power, S. ^{[7
]}

Bosco, J. ^{[7
]}

Mok, K. ^{[7
]}

机构：

[1] Cent Texas Neurol Consultants, Round Rock, TX USA

[2] Hope Neurol, Knoxville, TN USA

[3] Arcadia Neurol Ctr, Arcardia, CA USA

[4] Ohio State Univ, Dept Microbial Infect & Immun, Columbus, OH 43210 USA

[5] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA

[6] Neurol Ctr San Antonio, San Antonio, TX USA

[7] TG Therapeut, New York, NY USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1023

引用

页码：543 / 544

页数：2

共 50 条

[31] Long-term follow-up of initially benign multiple sclerosis patients: results from the Swedish multiple sclerosis register
Manouchehrinia, A.
Beiki, O.
Ramanujam, R.
Kavaliunas, A.
Glaser, A.
Hillert, J.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 719 - 720
[32] Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2
Comi, Giancarlo
Vollmer, Timothy
Lublin, Fred
Dadon, Yuval
Gorfine, Tali
Davis, Mat
Sorensen, Per Soelberg
Knappertz, Volker
NEUROLOGY, 2016, 86
[33] Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
Sharman, Jeff P.
Farber, Charles M.
Mahadevan, Daruka
Schreeder, Marshall T.
Brooks, Heather D.
Kolibaba, Kathryn S.
Fanning, Suzanne
Klein, Leonard
Greenwald, Daniel R.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Burke, John M.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 412 - 420
[34] Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients
Einsiedler, Maximilian
Kremer, Laurent
Fleury, Marie
Collongues, Nicolas
De Seze, Jerome
Bigaut, Kevin
JOURNAL OF NEUROLOGY, 2022, 269 (09) : 4846 - 4852
[35] Anti-CD20 immunotherapy in progressive multiple sclerosis: 2-year real-world follow-up of 108 patients
Maximilian Einsiedler
Laurent Kremer
Marie Fleury
Nicolas Collongues
Jérôme De Sèze
Kévin Bigaut
Journal of Neurology, 2022, 269 : 4846 - 4852
[36] Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves' orbitopathy: A five-year follow-up study
Erdei, Annamaria
Paragh, Gyorgy
Kovacs, Peter
Karanyi, Zsolt
Berenyi, Ervin
Galuska, Laszlo
Lenkey, Agota
Szabados, Lajos
Gyory, Ferenc
Ujhelyi, Bernadett
Berta, Andras
Boda, Judit
Berta, Eszter
Bodor, Miklos
Gazdag, Annamaria
Nagy, Endre V.
AUTOIMMUNITY, 2014, 47 (08) : 548 - 555
[37] Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study
Arianna Sartori
Mohammad Abdoli
Mark S. Freedman
Journal of Neurology, 2017, 264 : 1068 - 1075
[38] Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study
Sartori, Arianna
Abdoli, Mohammad
Freedman, Mark S.
JOURNAL OF NEUROLOGY, 2017, 264 (06) : 1068 - 1075
[39] A phase I dose-escalation trial of ublituximab (TG-1101), a novel anti-CD20 monoclonal antibody (mAb), for rituximab relapsed/refractory B-cell lymphoma patients
Deng, Changchun
Amengual, Jennifer Effie
Schreeder, Marshall T.
Clark-Garvey, Sean
Patterson, Molly
Miskin, Hari
Sportelli, Peter
O'Connor, Owen A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[40] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Salles, Gilles
Morschhauser, Franck
Lamy, Thierry
Milpied, Noel
Thieblemont, Catherine
Tilly, Herve
Bieska, Gabi
Asikanius, Elina
Carlile, David
Birkett, Joe
Pisa, Pavel
Cartron, Guillaume
BLOOD, 2012, 119 (22) : 5126 - 5132

← 1 2 3 4 5 →